Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.62M | -177.30M | -200.40M | -216.39M | -202.11M |
| Total Depreciation and Amortization | 603.00K | 566.00K | 534.00K | 556.00K | 581.00K |
| Total Amortization of Deferred Charges | 1.61M | 1.73M | 1.85M | 2.06M | 2.28M |
| Total Other Non-Cash Items | 3.09M | 1.11M | 5.01M | 7.75M | 7.06M |
| Change in Net Operating Assets | 13.42M | 6.47M | 14.24M | -1.81M | -3.65M |
| Cash from Operations | -101.90M | -167.43M | -178.78M | -207.84M | -195.84M |
| Capital Expenditure | -781.00K | -1.03M | -1.03M | -557.00K | -333.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 164.02M | 136.46M | -14.35M | -16.62M | -109.64M |
| Cash from Investing | 163.23M | 135.43M | -15.38M | -17.18M | -109.98M |
| Total Debt Issued | -- | -- | -- | -1.00K | 0.00 |
| Total Debt Repaid | -45.00M | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 1.00K | 89.00K | 89.00K | 89.00K |
| Repurchase of Common Stock | -597.00K | -597.00K | -1.76M | -1.73M | -1.94M |
| Issuance of Preferred Stock | -- | -- | 241.43M | 241.43M | 241.43M |
| Repurchase of Preferred Stock | -88.00K | -103.00K | -103.00K | -25.00K | -15.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -907.00K | -907.00K | -1.31M | -1.31M | -400.00K |
| Cash from Financing | -46.59M | -1.61M | 238.35M | 238.45M | 239.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.75M | -33.61M | 44.19M | 13.44M | -66.65M |